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Introduction: New oral anticoagulants are effective alternatives to warfarin. However, no specific reversal agents
are available for life-threatening bleeding or emergency surgery. Using a porcine model of trauma, this study
assessed the ability of prothrombin complex concentrate (PCC), activated PCC (aPCC), recombinant FVIIa (rFVIIa) and
a specific antidote to dabigatran (aDabi-Fab) to reverse the anticoagulant effects of dabigatran.
Methods: Dabigatran etexilate (DE) was given orally for 3 days (30 mg/kg bid) and intravenously on day 4 to
achieve consistent, supratherapeutic concentrations of dabigatran. Blood samples were collected at baseline, after
oral DE, after intravenous dabigatran, and 60 minutes post-injury. PCC (30 and 60 U/kg), aPCC (30 and 60 U/kg),
rFVIIa (90 and 180 μg/kg) and antidote (60 and 120 mg/kg) were added to blood samples ex-vivo. Coagulation was
assessed by thromboelastometry, global coagulation assays and diluted thrombin time.
Results: Plasma concentrations of dabigatran were 380 ± 106 ng/ml and 1423 ± 432 ng/ml after oral and
intravenous administration, respectively, and all coagulation parameters were affected by dabigatran. Both PCCs and
aDabi-Fab, but not rFVIIa, reversed the effects of dabigatran on thromboelastometry parameters and prothrombin
time. In contrast, aPTT was only normalised by aDabi-Fab. Plasma concentration (activity) of dabigatran remained
elevated after PCC and rFVIIa therapy, but was not measureable after aDabi-Fab.
Conclusion: In conclusion, PCC and aPCC were effective in reducing the anticoagulant effects of dabigatran under
different conditions, while aDabi-Fab fully corrected all coagulation measures and decreased the plasma concentration
of dabigatran below the limit of detection. No significant effects were observed with rFVIIa.Introduction
Uncontrolled post-traumatic bleeding is the leading
cause of potentially preventable death among trauma pa-
tients [1]. Early coagulation abnormalities are frequent
in severely injured trauma patients and are associated
with substantially increased mortality [2]. Patients’ ten-
dency towards perioperative and trauma-induced bleed-
ing is further increased by anticoagulant medication.
The direct oral anticoagulant (DOAC) dabigatran, a dir-
ect thrombin inhibitor, is administered orally as the pro-
drug dabigatran etexilate (DE) and is characterised by a* Correspondence: ogrottke@ukaachen.de
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unless otherwise stated.rapid onset of action, few drug or food interactions, no
requirement for routine coagulation monitoring and a
short half-life of 12 to 14 hours [3].
Dabigatran is approved in many countries for the pri-
mary prevention of venous thromboembolic events in
adult patients who have undergone elective total hip or
total knee replacement surgery, and/or for the preven-
tion of stroke and systemic embolism in adult patients
with non-valvular atrial fibrillation [3,4]. Dabigatran dir-
ectly inhibits both free and clot-bound thrombin, and
this impedes the conversion of fibrinogen to fibrin, thus
preventing thrombus development. Results from a large
multicentre randomised controlled trial including 18,113
patients with atrial fibrillation (RE-LY) suggest a low
overall risk of bleeding complications [5]. Because of thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recently, experience in the management of bleeding
complications associated with DOACs is limited. How-
ever, in the case of life-threatening bleeding following in-
jury, immediate and prompt reversal of anticoagulation
is required [6]. At the present time, no specific antidotes
are licensed for reversal of the anticoagulant effects of
dabigatran.
Experimental data show that dabigatran may be re-
moved from the circulation by dialysis [7]. This ap-
proach is reported to be effective in patients with end-
stage renal disease and several case reports have been
published showing that dialysis is effective in reducing
plasma concentrations of dabigatran [8-10]. However,
this procedure may not be feasible in haemodynamically
unstable patients with haemorrhagic shock. Prothrombin
complex concentrate (PCC), activated PCC (aPCC) and
recombinant activated factor VII (rFVIIa) have been pro-
posed as candidates for reversing the anticoagulant effects
of dabigatran. However, results from initial experimental
trials are inconclusive and they do not account for differ-
ent dabigatran concentrations or the combined effects of
dabigatran and severe injury such as trauma [11-13]. Data
from the few studies that have been performed in humans
are also inconclusive. One study of PCC in healthy volun-
teers previously receiving dabigatran showed an increase
in endogenous thrombin potential [14], whereas in an-
other study PCC did not reverse the effect of dabigatran
as measured by activated partial thromboplastin time
(aPTT) [15]. A specific antibody fragment to dabigatran
(aDabi-Fab) is in development, and in a rat model of antic-
oagulation it rapidly reversed the anticoagulant activity of
dabigatran [16]. However, this antidote is not yet licensed
for clinical use.
This porcine study was performed to evaluate the po-
tential use of commonly available haemostatic agents
(PCC, aPCC and rFVIIa), as well as the specific antidote
aDabi-Fab, to reverse dabigatran-induced coagulopathy in
an anticoagulation/trauma model. In addition, the study
investigated the sensitivity of different coagulation tests,
including thromboelastometry variables, for diagnosis and
reversal of dabigatran/trauma-induced coagulopathy.
Materials and methods
Ethics and anaesthesia
All experiments were performed in accordance with German
legislation governing animal studies following the Principles
of Laboratory Animal Care. Ethical approval for these studies
was obtained from the regional governmental animal care
and use office (No. 84–02.04.2012.A197). Before surgery,
pigs were housed in ventilated rooms and allowed to accli-
matise to their surroundings for a minimum of seven days.
Animals were fasted overnight before surgical procedures,
with unrestricted access to water.Prior to surgery, DE (Pradaxa, Boehringer Ingelheim,
Biberach, Germany) was administered orally twice daily
for 3 days (30 mg/kg bid). On the day of surgery, animals
received an intramuscular injection of 4 mg/kg azaperone
(Stresnil, Janssen, Neuss, Germany) and 0.1 mg/kg atro-
pine (atropine sulphate, B Braun, Melsungen, Germany)
as premedication. Anaesthesia was induced by intravenous
injection of 3 mg/kg propofol (Disoprivan, Astra Zeneca,
Wedel, Germany) followed by orotracheal intubation. The
animals were ventilated with a tidal volume of 8 mL/kg
and 16 to 22 breaths/minute (Cato, Draeger, Luebeck,
Germany) to maintain end-tidal carbon dioxide between
36 and 42 mmHg. Anaesthesia was maintained with iso-
flurane (Forane, Abbott Laboratories Inc., Abbott Park,
IL, USA) at an end-tidal concentration of 1% and a con-
tinuous infusion of fentanyl (Janssen, Neuss, Germany) at
3 to 4 μg/kg/h. Ringer’s solution (Sterofundin, Braun,
Germany) was infused at 4 mL/kg/h initially, increasing to
10 mL/kg/h after laparotomy until infliction of trauma.
Throughout the experiment, body temperature was main-
tained at 36.5 to 37.0°C with a warming blanket.
Monitoring included electrocardiography (ECG), tail
pulse oximetry, temperature, and arterial and central ven-
ous pressure measured by femoral catheters connected to
a standard anaesthesia monitor (AS/3, Datex Ohmeda,
Helsinki, Finland).
Surgical preparation and dabigatran infusion
Two 8.5-Fr catheters were surgically implanted in the
right and left jugular veins for volume substitution and in-
sertion of a pulmonary artery catheter. The right femoral
artery was cannulated with an 18-G catheter to collect
blood samples and to measure continuous arterial pres-
sure. After line placement, a midline laparotomy with
cystostomy was performed. Subsequently, dabigatran (ac-
tive substance; Boehringer Ingelheim, Biberach, Germany)
was infused at a rate of 0.77 mg/kg/h for 30 minutes and
0.52 mg/kg/h for 60 minutes to achieve consistent,
supratherapeutic plasma concentrations of dabigatran.
A reproducible blunt liver injury was induced by
clamping once through the parenchyma of the right
middle liver lobe, using a custom-made instrument; the
procedure has been described previously by our group
[17]. Five minutes after injury and following haemor-
rhagic shock, all animals received a fluid bolus of
35 mL/kg of Ringer’s solution followed by continuous
infusion of 40 mL/kg/h until four hours post-injury.
Sixty minutes after trauma, the abdomen was reopened
and the blood was collected to determine the total blood
loss post-injury.
Haemostatic agents
The following haemostatic agents were tested: PCC (Beriplex
P/N 250 (US brand-name Kcentra), CSL Behring GmbH,
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Baxter, Vienna, Austria; lot VNP5L003), and rFVIIa
(NovoSeven, NovoNordisk, Denmark; lot LR04350). In
addition, a specific antibody fragment to dabigatran
being developed as an antidote (aDabi-Fab, Boehringer
Ingelheim, Biberach, Germany; lot 6001325) was also
tested [16]. PCC, aPCC and rFVIIa were reconstituted with
sterile water according to the manufacturer’s instructions
immediately prior to administration. The aDabi-Fab was
obtained in Tween 20 buffer (25 mM acetate, 220 mM
sorbitol and 0.2% polysorbate 20) at a concentration of
44 mg/mL. Aliquots were stored at −80°C and thawed at
37°C for 10 minutes prior to application.
Blood collection and ex vivo addition of haemostatic
agents
Blood samples were collected into sodium citrate (Sarsted,
Nuembrecht, Germany) at the following four time points:
baseline (3 days before oral administration of dabigatran
was started), 12 h after the last oral dose of DE, which rep-
resents trough levels of dabigatran (low dabigatran level),
after the 90-minute dabigatran infusion, which repre-
sents peak levels of dabigatran (high dabigatran level)
and 60 minutes post-injury (post-trauma), which was
also 60 minutes after stopping the dabigatran infusion
and induction of blunt trauma injury. Placebo (saline),
PCC, aPCC, rFVIIa or aDabi-Fab was added ex vivo
to each citrated whole blood sample from each time
point. The concentration of PCC and aPCC added
was equivalent to the plasma concentrations achieved
with 30 U/kg and 60 U/kg; rFVIIa was similarly added to
achieve plasma levels equivalent to those achieved with
90 μg/kg and 180 μg/kg. aDabi-Fab was added at a con-
centration to achieve plasma levels equivalent to 30 or
60 mg/kg.
Analytical methods including coagulation assays and
thromboelastometry
Haemoglobin (Hb) concentrations were measured with a
blood gas analyser (ABL500, Radiometer, Copenhagen,
Denmark). Prothrombin time (PT, Innovin), aPTT (Actin
FS) and fibrinogen concentration (thrombin reagent) were
determined by standard laboratory methods using the ap-
propriate tests (all from Dade Behring, Marburg, Germany)
on a coagulometer (MC 4 plus, Merlin Medical, Lemgo,
Germany). Dabigatran plasma concentration was de-
termined using the diluted thrombin time (Hemoclot,
HyphenBiomed, Neuville sur-Oise, France).
Coagulation was assessed in whole blood using a
thromboelastometry device (ROTEM, Tem International
GmbH, Munich, Germany) and the EXTEM assay. The
following parameters were measured: clotting time (CT, s),
clot formation time (CFT, s) and maximum clot firmness
(MCF, mm).Statistical analysis
Statistical analysis was performed using PASW 18 (SPSS,
Chicago, IL, USA). For graphical purposes, GraphPad
Prism (Version 6.0, GraphPad Software, Inc., La Jolla,
CA, USA) was used. Differences between the control
and intervention groups were analysed with a one-way
analysis of variance (ANOVA), with the Dunnett post
hoc test for multiple comparisons. ‘Non-measurable’ was
entered for clot formation time (CFT) when the required
clot amplitude of 20 mm was not reached within
4,000 seconds. Data are presented as mean ± SD. Statis-
tical tests were performed two-tailed and P-values <0.05
were considered statistically significant.
Results
Five male German land-race pigs were included in this
ex vivo study; the animals’ bodyweights ranged between
37 and 42 kg.
Effects of oral administration of DE and intravenous
infusion of dabigatran
All coagulation parameters were within reference ranges
at baseline (grey dotted line in all figures). After three
days of oral DE, the mean plasma concentration of dabi-
gatran was 380 ± 106 ng/mL (low dabigatran, in Table 1).
Laboratory coagulation parameters were prolonged com-
pared with baseline: PT from 9 ± 1 to 25 ± 8 s and aPTT
from 13 ± 1 to 22 ± 4 s (control, Figures 1A and 2A). Ac-
cordingly, the EXTEM variables CT and CFT were also
substantially prolonged (control, Figure 3A and B). How-
ever, no effects of oral DE administration on clot strength
(MCF) or concentration of haemoglobin, platelets or fi-
brinogen were observed (control, Figure 3C and Table 2).
Following the 90-minute infusion of dabigatran, the mean
plasma concentration (activity) of dabigatran increased to
1423 ± 432 ng/mL. This supratherapeutic level was associ-
ated with a further prolongation of PT, aPTT, and the
EXTEM variables CT and CFT (Figures 1B, 2B and 4).
These changes in coagulation parameters were com-
pounded by blood loss following trauma (total blood loss
at 60 minutes 1978 ± 265 mL) and dilution following the
infusion of crystalloids. Sixty minutes after trauma, four
out of five animals had no measurable clot formation
(EXTEM CFT ≥4,000 s), and clot strength (EXTEM MCF)
had reduced to 11 ± 7 mm (Figure 5). At the same time,
plasma fibrinogen concentration had decreased to 64 ±
12 mg/dL and the mean haemoglobin level had dropped to
4.5 ± 0.6 g/L (Table 2). In addition, further prolongation of
PT and aPTT was seen (control, Figures 1C and 2C).
Measurements after haemostatic therapy ex vivo
Ex-vivo treatment with PCC
The effects of dabigatran anticoagulation, alone (after both
oral and intravenous administration) and compounded by
Table 1 Plasma concentration (activity, measured by diluted thrombin time) of dabigatran (ng/mL) during the study
Low dabigatran High dabigatran Post-trauma
Control 380 ± 106 1423 ± 432 1021 ± 238
PCC (30; 60 U/kg) 299 ± 101; 302 ±115 1276 ± 443; 1273 ± 479 814 ± 81; 801 ± 185
aPCC (30; 60 U/kg) 291 ± 108; 288 ± 107 1199 ± 452; 1188 ±449 785 ± 166; 795 ± 159
rFVIIa (90; 180 μg/kg) 270 ± 86; 267 ± 87 1266 ± 500; 1295 ± 496 766 ± 194; 797 ± 161
aDabi-Fab (30; 60 mg/kg) 0.0 ± 0.0; 0.0 ± 0.0 0.0 ± 0.0; 0.0 ± 0.0 0.0 ± 0.0; 0.0 ± 0.0
Because dabigatran etexilate had not been administered, plasma concentrations of dabigatran were not measured at baseline.
Data are shown as mean ± SD. PCC, prothrombin complex concentrate; aPCC, activated PCC; rFVIIa, recombinant activated factor VII; aDabi-Fab, antibody fragment
to dabigatran.
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shown by significant decreases versus control in PT, CT
and CFT (Figures 1, 3, 4 and 5). Increased effects were ap-
parent with the higher concentration of PCC after intraven-
ous administration of dabigatran (high plasma concentration
of dabigatran) and, in addition to the effects on PT, CT
and CFT, clot strength (EXTEM MCF) almost returned to
baseline with both doses of PCC. A similar pattern was
observed following trauma: PT, CT and CFT were signifi-
cantly shortened by PCC, and clot strength was returned
to levels close to baseline (Figures 1C and 5A-C). Despite
approximately 80 to 90% reversal of the effects on these
parameters, PCC treatment had no effect on aPTT at any
time point (Figure 2A-C), and the plasma level (activity,
measured by diluted thrombin time) of dabigatran was
also unchanged by PCC.
Ex vivo treatment with aPCC
Dabigatran-induced coagulopathy, both after oral intake
and infusion, was reversed by aPCC application, with very
similar response patterns to those observed with PCC
(Figures 1, 3, 4 and 5). Decreases in PT, CT and CFT were
observed, and MCF returned close to baseline after intra-
venous dabigatran and trauma, although, as with PCC
these parameters were not fully restored to baseline levels.
Also as with PCC, aPCC had no significant effect on aPTT
or levels of dabigatran.
Ex vivo treatment with rFVIIa
Ex-vivo addition of rFVIIa had no significant effect on any
of the coagulation parameters at any time point. This was
true for both doses of rFVIIa. In addition, rFVIIa had no
impact on the plasma concentration of dabigatran at any
time point.
Ex vivo treatment with aDabi-Fab
After oral DE and intravenous dabigatran, both concen-
trations of aDabi-Fab restored coagulation parameters
to their baseline values or similar. Even after trauma,
PT, aPTT, CT, and CFT were reversed to baseline values
(Figures 1C, 2C and 5), although a small decrease in MCF
was still apparent. The restoration of aPTT to baseline
values (Figure 2A-C) distinguished aDabi-Fab from PCCand aPCC. In addition, the mean plasma concentration of
dabigatran was below the limit of detection (that is, ap-
proximately zero) after the addition of both concentra-
tions of aDabi-Fab (Table 1).
Discussion
This experimental animal trial is the first to show
in vitro that PCC, aPCC and aDabi-Fab are effective for
the reversal of dabigatran-induced coagulopathy in a
model of anticoagulation and liver trauma. Coagulation
parameters, which were all affected by dabigatran ad-
ministration, were corrected most effectively by aDabi-
Fab, but, this product is yet to be licensed for clinical
use. It is therefore of potential clinical importance that
this study also suggests that PCC and aPCC could poten-
tially be used for emergency reversal of dabigatran. In con-
trast, rFVIIa had no significant impact on coagulation
after oral DE or intravenous dabigatran administration,
despite the use of relatively high-dose rFVIIa (equivalent
to 180 μg/kg).
Theoretically, the use of prothrombin (a major compo-
nent of PCC) may reverse the anticoagulation activity
of dabigatran by providing thrombin for the transform-
ation of fibrinogen to fibrin. PCCs and aPCCs are de-
rived from human plasma and most contain the vitamin
K-dependent coagulation factors II, VII, IX, and X. PCCs
with low levels of factor VII (3-factor PCCs) are com-
monly used in the USA, but products with higher levels
of factor VII (4-factor PCCs) are used more commonly
outside the USA. Based on the results of an open-label,
phase IIIb randomised controlled trial [18], the first
4-factor PCC (Kcentra, CSL Behring, Germany) has
been recently licensed in the US for the urgent rever-
sal of coagulation factor deficiency induced by vita-
min K antagonist (for example, warfarin) therapy in
adult patients with acute major bleeding [19,20]. Cur-
rently, there are two major indications for PCC: rapid re-
versal of oral anticoagulation (vitamin K antagonists) and
deficiency of vitamin K-dependent coagulation factors
in life-threatening bleeding. Unlike 4-factor or 3-factor
PCCs, aPCC (FEIBA, Baxter, USA) contains activated fac-
tors and is indicated for haemophilia A and haemophilia B


































































































































































































Figure 1 Prothrombin time at the low dabigatran (A), high
dabigatran (B) and post-trauma (C) time points. Prothrombin
time was obtained on a coagulometer using Innovin to determine
the effect of ex vivo haemostatic therapy at various time points. Grey
dotted lines indicate mean baseline values. *P <0.05 versus control.
PCC, prothrombin complex concentrate; aPCC, activated PCC; rFVIIa,










































































































































































Figure 2 aPTT at the low dabigatran (A), high dabigatran (B)
and post-trauma (C) time-points. Activated partial thromboplastin
time (aPTT) was obtained on a coagulometer to determine the
effect of hemostatic therapy at various time points. Grey dotted lines
indicate mean baseline values. Data are shown as mean ± SD.
*P <0.05 versus control. PCC, prothrombin complex concentrate;
aPCC, activated PCC; rFVIIa, recombinant activated factor VII;
aDabi-Fab, antibody fragment to dabigatran.

























































































































































































Figure 3 Thromboelastometry parameters after oral
administration of dabigatran etexilate. The ROTEM coagulation
analyzer (TEM international, Munich, Germany) was used for
thromboelastometry. For activation the ExTEM reagent containing
tissue factor as starting reagent was used according to the
manufacturer instructions. (A) The clotting time (CT) represents the
initiation of clot formation and corresponds to the reaction time.
(B) clot formation time (CFT) reflects the coagulation time until
20 mm of amplitude are reached. (C) The maximum clot firmness
(MCF) reflects the strength of a resulting clot. Data are shown as
mean ± SD. *P <0.05 versus control. PCC, prothrombin complex
concentrate; aPCC, activated PCC; rFVIIa, recombinant activated
factor VII; aDabi-Fab, antibody fragment to dabigatran.
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tions [21].
PCC has been successfully used to terminate serious
bleeding in pre-clinical studies [22-24]. Evidence from
pre-clinical studies also supports a potential role for the
use of PCC to reverse the effects of dabigatran [11-13].
In a rabbit model of anticoagulation associated with
dabigatran, the use of PCC significantly reduced blood
loss in a dose-dependent manner following a standar-
dised kidney incision [11]. Furthermore, in a murine
model of intracerebral haemorrhage, animals receiving
dabigatran twice daily showed an expansion of intracere-
bral haematoma on magnetic resonance imaging [13].
The use of PCC (up to 100 U/kg) was associated with
dose-dependent prevention of haematoma growth and
also reversal of prolonged tail bleeding time. In another
murine study, administration of PCC in combination
with rFVIIa or aPCC prior to tail tip resection signifi-
cantly reduced bleeding time but had no significant im-
pact on blood loss, although the dose of PCC used in
this study was low (14.3 U/kg) [12].
Few data exist on the use of PCC for the reversal of
the anticoagulant effects of dabigatran in humans. In
one study, following oral administration of dabigatran to
10 healthy volunteers, the capacity of thrombin gener-
ation was evaluated ex vivo. The intake of dabigatran
was shown to affect the kinetics of thrombin generation,
with a prolongation of the lag time and time to peak
[14]. The addition of PCC significantly increased the en-
dogenous thrombin potential, although no influence on
the lag time was observed. In contrast to this study, in a
trial of six healthy volunteers, PCC did not reverse the
prolongation of the aPTT resulting from standard oral
DE doses of 150 mg twice daily [15].
Although the investigators in the latter study used a dif-
ferent PCC (Cofact; Sanquin Blood Supply, Amsterdam,
the Netherlands) to the PCC used in this study (Beriplex
P/N 250, CSL Behring GmbH, Marburg, Germany), we
have previously shown the two PCCs to have a similar pat-
tern of thrombin generation [25]. Thus, discrepancy
between studies regarding the effect of PCC on plasma
Table 2 Haematological parameters and fibrinogen concentration during the study
Baseline Low dabigatran High dabigatran Post-trauma
Haemoglobin (g/L) 10.5 ± 0.7 10.2 ± 0.8 9.5 ± 0.4 4.5 ± 0.7
Platelets (× 103/μL) 388 ± 51 403 ± 36 355 ± 66 202 ± 50
Fibrinogen (mg/dL) 161 ± 16 135 ± 13 118 ± 19 64 ± 12
Data are shown as mean ± SD.
Grottke et al. Critical Care 2014, 18:R27 Page 7 of 10
http://ccforum.com/content/18/1/R27coagulation assays raises the question of which coagula-
tion test is adequate for monitoring the potential of a PCC
to reverse the anticoagulant effects of dabigatran. The re-
versal of the prolonged PT, but not prolonged aPTT by
PCC/aPCC in this study highlights the need for an assay
that is sensitive not only to the anticoagulant used, but
also to the effects of the reversal agent. In the case of war-
farin, the PT (or international normalized ratio) is
dependent on the vitamin K-dependent coagulation
factors [26] and therefore serves not only as a sensitive
measure of the effects of anticoagulation therapy, but also
of its reversal by PCCs or aPCC. Conversely, PT is an in-
sensitive measure of the effects of therapeutic doses of
dabigatran [26-28]. However, as shown in this study, a
high concentration of the drug can prolong the PT,
thus enabling the dabigatran-prolonged PT to be re-
versed by PCC and aPCC. aPTT is more sensitive
than PT to therapeutic levels of dabigatran [26,28],
but the lack of effects of PCCs and aPCCs on aPTT
suggests that this test is not suitable for monitoring re-
versal with these products. For confirmation of reversal of
dabigatran therapy in the presence of trauma-related
bleeding, well-designed studies with appropriate (sensi-
tive) coagulation assays are urgently warranted.
In this study, we used thromboelastometry to monitor
the effects of dabigatran. In the trauma setting, delays in
the detection of coagulopathy may influence outcome; in
contrast to the conventional coagulation tests, which are
associated with slower turnaround times, thromboelasto-
metry allows rapid assessment of a patient’s coagulopathy.
Based on findings from retrospective studies, thromboe-
lastometry appears to be a useful tool to guide PCC ther-
apy in patients with traumatic coagulopathy [29,30]. The
EXTEM assay is similar to PT in that it assesses tissue
factor-initiated extrinsic coagulation, making it the most
suitable thromboelastometric assay for investigating PCC
or aPCC reversal of dabigatran. There has been little
investigation of the effects of dabigatran on viscoelastic
coagulation parameters but, consistent with the present
findings, prolonged activated clotting time with rapid
thromboelastography was seen in several patients taking
dabigatran [31]. We found that PCC, aPCC and aDabi-
Fab reversed the anticoagulant effects of dabigatran as
shown by improvements in CT and CFT. It is important
to note that the decrease in MCF observed after dabiga-
tran infusion was mainly attributable to a decrease inthe amount of thrombin available for the conversion
of fibrinogen to fibrin, as opposed to insufficient clot
substrate (fibrinogen, platelets). Once sufficient thrombin
becomes available through addition of PCC, aPCC or
aDabi-Fab, transformation of fibrinogen to fibrin is re-
stored and clot formation is no longer impaired. Overall,
thromboelastometry may be useful in the detection of co-
agulopathy associated with dabigatran and in monitoring
the effects of reversal therapy.
A drawback of PCC use is the potential risk of thrombo-
embolic complications [24]. We have shown in an experi-
mental animal model of liver injury that high levels (50 U/kg)
of PCC may increase the risk for disseminated intravascu-
lar coagulation, and this was explained by an imbalance of
pro- and anti-coagulant proteins [24]. However, there has
been a suggestion that the procoagulant effects of high-
dose PCC are reduced in the presence of dabigatran [32];
the safety profile of PCC or aPCC for the reversal of dabi-
gatran remains to be characterised.
rFVIIa is approved to treat haemophilia patients with
inhibiting antibodies against coagulation factors VIII or
IX [33]. The use of this agent in patients with bleeding
trauma who are resistant to conventional haemostatic
therapy, even as a last resort, may be considered as sur-
prising given that a large randomised controlled trial
(CONTROL) was stopped after an analysis predicted
that the likelihood of a successful outcome concerning
the primary endpoints (mortality and morbidity) was
very low [34]. In the present study, rFVIIa had no effect
on reversal of any coagulation parameters. This is con-
sistent with previous data demonstrating lack of effect of
rFVIIa on dabigatran-induced bleeding in a murine
model of haemorrhagic stroke [13]. These findings may
be explained by the mechanism of action of rFVIIa: it in-
fluences the kinetics of thrombin generation, but it does
not increase the concentration of prothrombin.
The results of this in vitro study have shown the spe-
cific antidote to dabigatran, aDabi-Fab, to have the great-
est impact on all coagulation variables at all measured
time points. Dabigatran, even at supratherapeutic concen-
trations (1,400 to 1,500 ng/mL, compared with the normal
therapeutic range in humans of 50 to 250 ng/mL), was
completely neutralised after the addition of aDabi-Fab.
This is in line with results from a previous rat model of
anticoagulation in which a single bolus injection of aDabi-
































































































































































































Figure 4 Thromboelastometry parameters after intravenous
administration of dabigatran. After 90 minutes of intravenous
infusion of dabigatran, the EXTEM assay was performed using a
ROTEM device. Data are shown as mean ± SD. *P <0.05 versus
control. PCC, prothrombin complex concentrate; aPCC, activated



































































































































































































Figure 5 Thromboelastometry parameters 60 minutes after
trauma. Sixty minutes after stopping the dabigatran infusion and
the infliction of blunt liver injury trauma, a ROTEM device was used
to measure the impact of dabigatran reversal. Data are shown as the
mean ± SD. *P <0.05 versus control. PCC, prothrombin complex
concentrate; aPCC, activated PCC; rFVIIa, recombinant activated
factor VII; aDabi-Fab, antibody fragment to dabigatran.
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mately 25 minutes despite continued infusion of dabiga-
tran [16]. The increased potency of aDabi-Fab in
comparison with PCC, aPCC and rFVIIa is undoubtedly
related to their different mechanisms of action. The
aDabi-Fab binds directly to dabigatran in plasma or whole
blood and inactivates it, thus all coagulation measure-
ments are returned to baseline. In contrast, PCC, aPCC
and rFVIIa do not bind to dabigatran. Instead, these drugs
overcome the anticoagulant activity by increasing the
availability of substrate for coagulation.
There are some limitations of our study that need to
be acknowledged. Haemostatic agents and aDabi-Fab
were supplemented ex vivo. This approach was taken
mainly for ethical reasons: it enabled investigation of a
variety of haemostatic agents with a small number of an-
imals. As a consequence, however, the effects of treat-
ment on blood loss could not be measured and it is
uncertain to what extent our observations may be pre-
dictive of clinical dabigatran reversal. This uncertainty was
in part mitigated by the use of intravenous dabigatran in
its active form rather than the orally administered pro-
drug DE. Thus, possible species-related differences in drug
absorption and conversion to active form cannot have in-
fluenced the present data. However, there remains a possi-
bility of species differences in aspects such as the tissue
factor/rFVIIa complex, and the aPTT/PT responses to
dabigatran [35]. Another consideration regarding applic-
ability to the clinical setting is the plasma level of dabiga-
tran. Mean levels at the low dabigatran timepoint were
slightly above the normal therapeutic range, with higher
values with high dabigatran and post-trauma. Although
our study would have been improved by matching more
closely the normal therapeutic range of dabigatran levels,
it seems reasonable to assume that if reversal is successful
at supratherapeutic concentrations, it would also be suc-
cessful at lower, therapeutic levels. Clinical data from
human patients receiving dabigatran therapy are clearly
needed to confirm the efficacy, optimal dosing and safety of
PCC, aPCC and aDabi-Fab for the reversal of dabigatran.
Conclusion
In summary, dabigatran-induced coagulopathy was re-
versed by ex vivo administration of two different doses
of exogenous PCC and aPCC in this porcine model of
anticoagulation and blunt liver injury. In contrast, ex vivo
rFVIIa had no significant effect on coagulation parameters
after administration of dabigatran. Unlike PCC or aPCC,
ex vivo addition of aDabi-Fab provided complete neutral-
isation of dabigatran as well as full reversal of its effects.
However, aDabi-Fab is still in development and is there-
fore not yet available for clinical use. Although further
data investigating the effects of aDabi-Fab and PCCs are
urgently needed, the administration of PCC or aPCCcould potentially be considered as a therapeutic option to
control life-threatening bleeding among patients under
treatment with dabigatran.
Key messages
 PCC and aPCC effectively reverse dabigatran-
induced coagulopathy in an anticoagulation/liver
trauma model.
 rFVIIa has no significant effect on coagulation in
this setting.
 aDabi-Fab provides the most effective reversal of the
anticoagulant effects of dabigatran.
 Thromboelastometry variables may help to guide
therapy in patients receiving dabigatran.
 Until aDabi-Fab becomes available, administration of
PCC or aPCC might be a reasonable intervention
for dabigatran-treated patients with life-threatening
bleeding.
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